Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial ; volume:15 ; number:1 ; day:3 ; month:4 ; year:2014 ; pages:1-9 ; date:12.2014
Trials ; 15, Heft 1 (3.4.2014), 1-9, 12.2014
- Creator
-
Eskandary, Farsad
- Contributor
-
Bond, Gregor
Schwaiger, Elisabeth
Kikic, Zeljko
Winzer, Christine
Wahrmann, Markus
Marinova, Lena
Haslacher, Helmuth
Regele, Heinz
Oberbauer, Rainer
Böhmig, Georg A.
SpringerLink (Online service)
- DOI
-
10.1186/1745-6215-15-107
- URN
-
urn:nbn:de:1111-2016050236311
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Eskandary, Farsad
- Bond, Gregor
- Schwaiger, Elisabeth
- Kikic, Zeljko
- Winzer, Christine
- Wahrmann, Markus
- Marinova, Lena
- Haslacher, Helmuth
- Regele, Heinz
- Oberbauer, Rainer
- Böhmig, Georg A.
- SpringerLink (Online service)
Other Objects (12)
HLA antibody-mediated pathways in human endothelial cells and transplant rejection
Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
The challenge to detect heart transplant rejection and transplant vasculopathy non-invasively - a pilot study
Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats : Antibody-mediated rejection of arterialised venousallografts is inhibited by immunosuppression in rats
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: a preliminary experience
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
HLA antibody-mediated pathways in human endothelial cells and transplant rejection
Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
The challenge to detect heart transplant rejection and transplant vasculopathy non-invasively - a pilot study
Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats : Antibody-mediated rejection of arterialised venousallografts is inhibited by immunosuppression in rats
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: a preliminary experience
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
HLA antibody-mediated pathways in human endothelial cells and transplant rejection
Treatment of chronic active antibody-mediated rejection in renal transplant recipients – a single center retrospective study
Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
Risk of cellular or antibody-mediated rejection in pediatric kidney transplant recipients with BK polyomavirus replication—an international CERTAIN registry study
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
Misidentification of preformed anti-HLA-DP antibodies leads to antibody-mediated kidney transplant rejection: a case report
The challenge to detect heart transplant rejection and transplant vasculopathy non-invasively - a pilot study
Antibody-mediated rejection of arterialised venous allografts is inhibited by immunosuppression in rats : Antibody-mediated rejection of arterialised venousallografts is inhibited by immunosuppression in rats
Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: a preliminary experience